S.C. Ropharma（RPH）株式概要S.C. Ropharma S.A.はルーマニアで薬局チェーンを展開している。 詳細RPH ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績2/6財務の健全性6/6配当金0/6報酬当社が推定した公正価値より47.4%で取引されている 今年は黒字化を達成 リスク分析過去5年間で収益は年間37.2%減少しました。 意味のある時価総額がありません ( RON104M )すべてのリスクチェックを見るRPH Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW489,440 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG489,440 investors already sharing narrativesYour Fair ValueRON Current PriceRON 0.2013.3% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-725k3b2016201920222025202620282031Revenue RON 3.0bEarnings RON 7.4mAdvancedSet Fair ValueView all narrativesS.C. Ropharma S.A. 競合他社Farmaceutica REMEDIASymbol: BVB:RMAHMarket cap: RON 79.8mS.C. BucurSymbol: BVB:BUCVMarket cap: RON 100.8mS.C. ComcerealSymbol: BVB:CBOTMarket cap: RON 31.0mMiahelsa HoldingsSymbol: TSE:7129Market cap: JP¥3.2b価格と性能株価の高値、安値、推移の概要S.C. Ropharma過去の株価現在の株価RON 0.2052週高値RON 0.2352週安値RON 0.15ベータ0.351ヶ月の変化2.51%3ヶ月変化0%1年変化20.71%3年間の変化6.81%5年間の変化-8.93%IPOからの変化-54.67%最新ニュースお知らせ • Jun 01S.C. Ropharma S.A. to Report Q3, 2026 Results on Nov 27, 2026S.C. Ropharma S.A. announced that they will report Q3, 2026 results on Nov 27, 2026お知らせ • May 31S.C. Ropharma S.A. to Report Q1, 2026 Results on May 29, 2026S.C. Ropharma S.A. announced that they will report Q1, 2026 results at 6:00 PM, E. Europe Standard Time on May 29, 2026New Risk • May 28New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 28% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 35% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (RON102.3m market cap, or US$22.7m).お知らせ • Apr 28S.C. Ropharma S.A. to Report Fiscal Year 2025 Results on Apr 28, 2026S.C. Ropharma S.A. announced that they will report fiscal year 2025 results on Apr 28, 2026お知らせ • Mar 27S.C. Ropharma S.A., Annual General Meeting, Apr 27, 2026S.C. Ropharma S.A., Annual General Meeting, Apr 27, 2026, at 12:00 E. Europe Standard Time. Location: company s headquarters in brasov, 55, iuliu maniu street, RomaniaNew Risk • Jan 01New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 27% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 31% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (RON92.0m market cap, or US$21.2m).最新情報をもっと見るRecent updatesお知らせ • Jun 01S.C. Ropharma S.A. to Report Q3, 2026 Results on Nov 27, 2026S.C. Ropharma S.A. announced that they will report Q3, 2026 results on Nov 27, 2026お知らせ • May 31S.C. Ropharma S.A. to Report Q1, 2026 Results on May 29, 2026S.C. Ropharma S.A. announced that they will report Q1, 2026 results at 6:00 PM, E. Europe Standard Time on May 29, 2026New Risk • May 28New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 28% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 35% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (RON102.3m market cap, or US$22.7m).お知らせ • Apr 28S.C. Ropharma S.A. to Report Fiscal Year 2025 Results on Apr 28, 2026S.C. Ropharma S.A. announced that they will report fiscal year 2025 results on Apr 28, 2026お知らせ • Mar 27S.C. Ropharma S.A., Annual General Meeting, Apr 27, 2026S.C. Ropharma S.A., Annual General Meeting, Apr 27, 2026, at 12:00 E. Europe Standard Time. Location: company s headquarters in brasov, 55, iuliu maniu street, RomaniaNew Risk • Jan 01New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 27% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 31% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (RON92.0m market cap, or US$21.2m).Reported Earnings • Dec 27Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: RON392.9m (up 12% from 3Q 2024). Net income: RON3.93m (up 429% from 3Q 2024). Profit margin: 1.0% (up from 0.2% in 3Q 2024). The increase in margin was driven by higher revenue.New Risk • Sep 16New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 38% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 27% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (RON91.0m market cap, or US$21.3m).New Risk • May 09New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 7.6% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (7.6% operating cash flow to total debt). Earnings have declined by 15% per year over the past 5 years. Minor Risk Market cap is less than US$100m (RON78.2m market cap, or US$17.2m).Reported Earnings • May 09Full year 2024 earnings releasedFull year 2024 results: Revenue: RON1.33b (up 19% from FY 2023). Net loss: RON1.73m (down 122% from profit in FY 2023).お知らせ • Mar 27S.C. Ropharma S.A., Annual General Meeting, Apr 28, 2025S.C. Ropharma S.A., Annual General Meeting, Apr 28, 2025, at 12:30 E. Europe Standard Time. Location: at st. constantine hospital conference room in, brasov, 318 calea bucuresti, RomaniaNew Risk • Mar 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.9% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (6.6% average weekly change). Profit margins are more than 30% lower than last year (0.003% net profit margin). Market cap is less than US$100m (RON79.2m market cap, or US$17.4m).New Risk • Feb 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Romanian stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.9% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Profit margins are more than 30% lower than last year (0.003% net profit margin). Market cap is less than US$100m (RON81.8m market cap, or US$17.1m).分析記事 • Dec 06S.C. Ropharma (BVB:RPH) Is Experiencing Growth In Returns On CapitalWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? In a...New Risk • Sep 06New major risk - Revenue and earnings growthEarnings have declined by 2.9% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.9% per year over the past 5 years. Minor Risks Profit margins are more than 30% lower than last year (0.003% net profit margin). Market cap is less than US$100m (RON91.5m market cap, or US$20.4m).New Risk • Mar 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Large one-off items impacting financial results. Market cap is less than US$100m (RON97.7m market cap, or US$21.4m).分析記事 • Dec 09Here's What's Concerning About S.C. Ropharma's (BVB:RPH) Returns On CapitalFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. No independent directors (7 non-independent directors). Member of the Board of Directors Ovidiu Nut was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.分析記事 • Sep 23S.C. Ropharma (BVB:RPH) Is Reinvesting At Lower Rates Of ReturnFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...分析記事 • Jun 01Is S.C. Ropharma (BVB:RPH) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. No independent directors (7 non-independent directors). Member of the Board of Directors Ovidiu Nut was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.分析記事 • Mar 16Some Investors May Be Worried About S.C. Ropharma's (BVB:RPH) Returns On CapitalIf you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...Price Target Changed • Jul 26Price target decreased to RON0.23Down from RON0.38, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of RON0.22. Stock is down 7.5% over the past year.分析記事 • May 15S.C. Ropharma (BVB:RPH) Takes On Some Risk With Its Use Of DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Mar 26S.C. Ropharma (BVB:RPH) Might Be Having Difficulty Using Its Capital EffectivelyFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Is New 90 Day High Low • Feb 09New 90-day high: RON0.24The company is up 6.0% from its price of RON0.22 on 11 November 2020. The Romanian market is up 17% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Consumer Retailing industry, which is also up 6.0% over the same period.Is New 90 Day High Low • Jan 14New 90-day high: RON0.24The company is up 8.0% from its price of RON0.22 on 15 October 2020. The Romanian market is up 16% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Consumer Retailing industry, which is also up 8.0% over the same period.Is New 90 Day High Low • Dec 30New 90-day high: RON0.24The company is up 6.0% from its price of RON0.22 on 01 October 2020. The Romanian market is up 7.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is up 4.0% over the same period.分析記事 • Dec 23Should You Be Impressed By S.C. Ropharma's (BVB:RPH) Returns on Capital?What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...分析記事 • Nov 24We Wouldn't Rely On S.C. Ropharma's (BVB:RPH) Statutory Earnings As A GuideStatistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. Having said...Is New 90 Day High Low • Nov 16New 90-day low: RON0.21The company is down 11% from its price of RON0.24 on 18 August 2020. The Romanian market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is down 2.0% over the same period.Is New 90 Day High Low • Oct 29New 90-day low: RON0.21The company is down 11% from its price of RON0.24 on 30 July 2020. The Romanian market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is down 2.0% over the same period.Reported Earnings • Oct 09First half earnings releasedOver the last 12 months the company has reported total profits of RON5.44m, down 40% from the prior year. Total revenue was RON768.4m over the last 12 months, largely unchanged from the prior year.Is New 90 Day High Low • Oct 08New 90-day low: RON0.22The company is down 24% from its price of RON0.29 on 09 July 2020. The Romanian market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is up 3.0% over the same period.Is New 90 Day High Low • Sep 29New 90-day low: RON0.22The company is down 23% from its price of RON0.29 on 26 June 2020. The Romanian market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is up 2.0% over the same period.株主還元RPHRO Consumer RetailingRO 市場7D1.0%7.2%0.07%1Y20.7%26.2%70.9%株主還元を見る業界別リターン: RPH過去 1 年間で26.2 % の収益を上げたRO Consumer Retailing業界を下回りました。リターン対市場: RPHは、過去 1 年間で70.9 % のリターンを上げたRO市場を下回りました。価格変動Is RPH's price volatile compared to industry and market?RPH volatilityRPH Average Weekly Movement2.9%Consumer Retailing Industry Average Movement3.9%Market Average Movement4.9%10% most volatile stocks in RO Market12.3%10% least volatile stocks in RO Market2.7%安定した株価: RPH 、 RO市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: RPHの 週次ボラティリティ ( 3% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19521,758Mihai Mironwww.ropharma.roS.C. Ropharma S.A. はルーマニアで薬局チェーンを展開している。医薬品倉庫を通じて、一般用医薬品、食品サプリメント、化粧品、医療機器、皮膚化粧品、医薬部外品、その他の医薬品を販売している。また、心臓血管薬、皮膚薬、消化器薬、眼科薬、骨関節薬、呼吸器薬、泌尿生殖器薬、糖尿病薬なども取り扱っている。さらに、免疫サプリメント、抗酸化剤、ビタミン・ミネラル医薬品、子供用食品・サプリメント、妊娠・授乳用医薬品、子供用化粧品、紙おむつ、ナプキン、防虫剤なども提供している。さらに、ボディケア、ヘアケア、スキンケア製品、口腔衛生、日焼け防止、ハンドケア、フットケア、防虫製品も提供している。さらに、不妊治療薬、コンドーム、妊娠・排卵検査薬、生殖トニックも提供している。さらに、医療機器、保護メガネ、防水絆創膏も提供している。S C.ロファルマS.A.は1952年に設立され、ルーマニアのブラショフを拠点としている。もっと見るS.C. Ropharma S.A. 基礎のまとめS.C. Ropharma の収益と売上を時価総額と比較するとどうか。RPH 基礎統計学時価総額RON 104.30m収益（TTM）RON 3.95m売上高(TTM)RON 1.59b26.4xPER（株価収益率0.1xP/SレシオRPH は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計RPH 損益計算書（TTM）収益RON 1.59b売上原価RON 1.27b売上総利益RON 327.00mその他の費用RON 323.05m収益RON 3.95m直近の収益報告Mar 31, 2026次回決算日Aug 31, 2026一株当たり利益（EPS）0.0077グロス・マージン20.51%純利益率0.25%有利子負債／自己資本比率28.4%RPH の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/10 22:50終値2026/07/10 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋S.C. Ropharma S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jun 01S.C. Ropharma S.A. to Report Q3, 2026 Results on Nov 27, 2026S.C. Ropharma S.A. announced that they will report Q3, 2026 results on Nov 27, 2026
お知らせ • May 31S.C. Ropharma S.A. to Report Q1, 2026 Results on May 29, 2026S.C. Ropharma S.A. announced that they will report Q1, 2026 results at 6:00 PM, E. Europe Standard Time on May 29, 2026
New Risk • May 28New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 28% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 35% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (RON102.3m market cap, or US$22.7m).
お知らせ • Apr 28S.C. Ropharma S.A. to Report Fiscal Year 2025 Results on Apr 28, 2026S.C. Ropharma S.A. announced that they will report fiscal year 2025 results on Apr 28, 2026
お知らせ • Mar 27S.C. Ropharma S.A., Annual General Meeting, Apr 27, 2026S.C. Ropharma S.A., Annual General Meeting, Apr 27, 2026, at 12:00 E. Europe Standard Time. Location: company s headquarters in brasov, 55, iuliu maniu street, Romania
New Risk • Jan 01New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 27% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 31% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (RON92.0m market cap, or US$21.2m).
お知らせ • Jun 01S.C. Ropharma S.A. to Report Q3, 2026 Results on Nov 27, 2026S.C. Ropharma S.A. announced that they will report Q3, 2026 results on Nov 27, 2026
お知らせ • May 31S.C. Ropharma S.A. to Report Q1, 2026 Results on May 29, 2026S.C. Ropharma S.A. announced that they will report Q1, 2026 results at 6:00 PM, E. Europe Standard Time on May 29, 2026
New Risk • May 28New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 28% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 35% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (RON102.3m market cap, or US$22.7m).
お知らせ • Apr 28S.C. Ropharma S.A. to Report Fiscal Year 2025 Results on Apr 28, 2026S.C. Ropharma S.A. announced that they will report fiscal year 2025 results on Apr 28, 2026
お知らせ • Mar 27S.C. Ropharma S.A., Annual General Meeting, Apr 27, 2026S.C. Ropharma S.A., Annual General Meeting, Apr 27, 2026, at 12:00 E. Europe Standard Time. Location: company s headquarters in brasov, 55, iuliu maniu street, Romania
New Risk • Jan 01New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 27% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 31% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (RON92.0m market cap, or US$21.2m).
Reported Earnings • Dec 27Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: RON392.9m (up 12% from 3Q 2024). Net income: RON3.93m (up 429% from 3Q 2024). Profit margin: 1.0% (up from 0.2% in 3Q 2024). The increase in margin was driven by higher revenue.
New Risk • Sep 16New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 38% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 27% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (RON91.0m market cap, or US$21.3m).
New Risk • May 09New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 7.6% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (7.6% operating cash flow to total debt). Earnings have declined by 15% per year over the past 5 years. Minor Risk Market cap is less than US$100m (RON78.2m market cap, or US$17.2m).
Reported Earnings • May 09Full year 2024 earnings releasedFull year 2024 results: Revenue: RON1.33b (up 19% from FY 2023). Net loss: RON1.73m (down 122% from profit in FY 2023).
お知らせ • Mar 27S.C. Ropharma S.A., Annual General Meeting, Apr 28, 2025S.C. Ropharma S.A., Annual General Meeting, Apr 28, 2025, at 12:30 E. Europe Standard Time. Location: at st. constantine hospital conference room in, brasov, 318 calea bucuresti, Romania
New Risk • Mar 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.9% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (6.6% average weekly change). Profit margins are more than 30% lower than last year (0.003% net profit margin). Market cap is less than US$100m (RON79.2m market cap, or US$17.4m).
New Risk • Feb 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Romanian stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.9% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Profit margins are more than 30% lower than last year (0.003% net profit margin). Market cap is less than US$100m (RON81.8m market cap, or US$17.1m).
分析記事 • Dec 06S.C. Ropharma (BVB:RPH) Is Experiencing Growth In Returns On CapitalWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? In a...
New Risk • Sep 06New major risk - Revenue and earnings growthEarnings have declined by 2.9% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.9% per year over the past 5 years. Minor Risks Profit margins are more than 30% lower than last year (0.003% net profit margin). Market cap is less than US$100m (RON91.5m market cap, or US$20.4m).
New Risk • Mar 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Large one-off items impacting financial results. Market cap is less than US$100m (RON97.7m market cap, or US$21.4m).
分析記事 • Dec 09Here's What's Concerning About S.C. Ropharma's (BVB:RPH) Returns On CapitalFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. No independent directors (7 non-independent directors). Member of the Board of Directors Ovidiu Nut was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
分析記事 • Sep 23S.C. Ropharma (BVB:RPH) Is Reinvesting At Lower Rates Of ReturnFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
分析記事 • Jun 01Is S.C. Ropharma (BVB:RPH) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. No independent directors (7 non-independent directors). Member of the Board of Directors Ovidiu Nut was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
分析記事 • Mar 16Some Investors May Be Worried About S.C. Ropharma's (BVB:RPH) Returns On CapitalIf you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...
Price Target Changed • Jul 26Price target decreased to RON0.23Down from RON0.38, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of RON0.22. Stock is down 7.5% over the past year.
分析記事 • May 15S.C. Ropharma (BVB:RPH) Takes On Some Risk With Its Use Of DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • Mar 26S.C. Ropharma (BVB:RPH) Might Be Having Difficulty Using Its Capital EffectivelyFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Is New 90 Day High Low • Feb 09New 90-day high: RON0.24The company is up 6.0% from its price of RON0.22 on 11 November 2020. The Romanian market is up 17% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Consumer Retailing industry, which is also up 6.0% over the same period.
Is New 90 Day High Low • Jan 14New 90-day high: RON0.24The company is up 8.0% from its price of RON0.22 on 15 October 2020. The Romanian market is up 16% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Consumer Retailing industry, which is also up 8.0% over the same period.
Is New 90 Day High Low • Dec 30New 90-day high: RON0.24The company is up 6.0% from its price of RON0.22 on 01 October 2020. The Romanian market is up 7.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is up 4.0% over the same period.
分析記事 • Dec 23Should You Be Impressed By S.C. Ropharma's (BVB:RPH) Returns on Capital?What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...
分析記事 • Nov 24We Wouldn't Rely On S.C. Ropharma's (BVB:RPH) Statutory Earnings As A GuideStatistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. Having said...
Is New 90 Day High Low • Nov 16New 90-day low: RON0.21The company is down 11% from its price of RON0.24 on 18 August 2020. The Romanian market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is down 2.0% over the same period.
Is New 90 Day High Low • Oct 29New 90-day low: RON0.21The company is down 11% from its price of RON0.24 on 30 July 2020. The Romanian market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is down 2.0% over the same period.
Reported Earnings • Oct 09First half earnings releasedOver the last 12 months the company has reported total profits of RON5.44m, down 40% from the prior year. Total revenue was RON768.4m over the last 12 months, largely unchanged from the prior year.
Is New 90 Day High Low • Oct 08New 90-day low: RON0.22The company is down 24% from its price of RON0.29 on 09 July 2020. The Romanian market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is up 3.0% over the same period.
Is New 90 Day High Low • Sep 29New 90-day low: RON0.22The company is down 23% from its price of RON0.29 on 26 June 2020. The Romanian market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is up 2.0% over the same period.
